Early Response Assessment to Targeted Therapy Using 30-deoxy-30[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer

Kalevi Kairemo; Elmer B. Santos; Homer A. Macapinlac; Vivek Subbiah

doi:10.3390/diagnostics10010026

Early Response Assessment to Targeted Therapy Using 3⁰-deoxy-3⁰[(18)F]-Fluorothymidine (¹⁸F-FLT) PET/CT in Lung Cancer

Kalevi Kairemo, Elmer B. Santos, Homer A. Macapinlac, Vivek Subbiah

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 3⁰-deoxy-3⁰[(18)F]-fluorothymidine (¹⁸F-FLT) PET/CT. The superiority of ¹⁸F-FLT PET/CT over ¹⁸F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of ¹⁸F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days.

Original language	English (US)
Article number	26
Journal	Diagnostics
Volume	10
Issue number	1
DOIs	https://doi.org/10.3390/diagnostics10010026
State	Published - 2020

Keywords

F-FLT
F-FLT PET/CT
Lung cancer
Non-small cell lung cancer
Response to therapy
Small cell lung cancer

ASJC Scopus subject areas

Clinical Biochemistry

Access to Document

10.3390/diagnostics10010026

Cite this

@article{a025a6dfb3644f289cfb0ff42b9a7562,

title = "Early Response Assessment to Targeted Therapy Using 30-deoxy-30[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer",

abstract = "Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 30-deoxy-30[(18)F]-fluorothymidine (18F-FLT) PET/CT. The superiority of 18F-FLT PET/CT over 18F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of 18F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days.",

keywords = "F-FLT, F-FLT PET/CT, Lung cancer, Non-small cell lung cancer, Response to therapy, Small cell lung cancer",

author = "Kalevi Kairemo and Santos, {Elmer B.} and Macapinlac, {Homer A.} and Vivek Subbiah",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors.",

year = "2020",

doi = "10.3390/diagnostics10010026",

language = "English (US)",

volume = "10",

journal = "Diagnostics",

issn = "2075-4418",

publisher = "MDPI AG",

number = "1",

}

TY - JOUR

T1 - Early Response Assessment to Targeted Therapy Using 30-deoxy-30[(18)F]-Fluorothymidine (18F-FLT) PET/CT in Lung Cancer

AU - Kairemo, Kalevi

AU - Santos, Elmer B.

AU - Macapinlac, Homer A.

AU - Subbiah, Vivek

PY - 2020

Y1 - 2020

N2 - Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 30-deoxy-30[(18)F]-fluorothymidine (18F-FLT) PET/CT. The superiority of 18F-FLT PET/CT over 18F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of 18F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days.

AB - Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 30-deoxy-30[(18)F]-fluorothymidine (18F-FLT) PET/CT. The superiority of 18F-FLT PET/CT over 18F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of 18F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days.

KW - F-FLT

KW - F-FLT PET/CT

KW - Lung cancer

KW - Non-small cell lung cancer

KW - Response to therapy

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85078443267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078443267&partnerID=8YFLogxK

U2 - 10.3390/diagnostics10010026

DO - 10.3390/diagnostics10010026

M3 - Article

C2 - 31935818

AN - SCOPUS:85078443267

SN - 2075-4418

VL - 10

JO - Diagnostics

JF - Diagnostics

IS - 1

M1 - 26

ER -